- Principal risks
- 8 · 1 rising
| 25 Jul 2023 | Annual Report and Accounts (to 2023-03-31) | |
| 16 Sep 2022 | Annual Report and Accounts (to 2022-03-31) | |
| 18 Oct 2021 | Annual Report and Accounts (to 2021-03-31) |
ReNeuron is a prominent player in the field of cell-based therapies, utilizing its innovative stem cell technologies to create readily available stem cell treatments that do not require immunosuppressive medication.
| 25 Jul 2023 | Annual Report and Accounts (to 2023-03-31) | |
| 16 Sep 2022 | Annual Report and Accounts (to 2022-03-31) | |
| 18 Oct 2021 | Annual Report and Accounts (to 2021-03-31) |
ReNeuron is a prominent player in the field of cell-based therapies, utilizing its innovative stem cell technologies to create readily available stem cell treatments that do not require immunosuppressive medication.